Pharma Contract Manufacturers

Supported by solid demand, disciplined execution, and capex programs progressing as planned, Sai Life management remains confident in sustaining positive growth momentum.

The management expects better Q4 and a decent overall growth in FY27

In H1FY26, total revenue of the Sai Life Sciences increased by 53% YoY at ₹1,034 crore, driven by healthy growth across both the CRO and the CDMO business.

At 11:29 AM, Laurus Labs' stock was quoting 2 per cent higher at ₹943.15 on the BSE, commanding an m-cap of ₹50,913 crore, exchange data shows

A host of lesser-known vaccine makers are eyeing contract manufacturing opportunities for global and domestic majors

Contract manufacturers claim that at least 40-60% of pharmaceutical manufacturing in the country is outsourced by big pharma